Silexion Therapeutics Corp (SLXN) News
Track canonical SquawkNews coverage tagged to SLXN, Silexion Therapeutics Corp. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 12 indexed stories across 7 publication days and is ordered by the same first-publication timeline used by LiveCast.
H
Why GlucoTrack Shares Are Trading Higher By Around 118%; Here Are 20 Stocks Moving Premarket
Shares of GlucoTrack Inc (NASDAQ: GCTK ) rose sharply in pre-market trading following the announcement that its subsidiary, Lokahi Therapeutics, signed its first external, fee-for-service partnership. Innovate GBM, a non
LIVE | Sep 24, 2026, 09:05 AM UTC
L
Silexion Therapeutics to participate in September 2026 industry conferences
Silexion Therapeutics announced management will participate in September 2026 Industry and Investor Conferences. The company is a clinical-stage biotechnology focused on RNA interference (RNAi) therapies for KRAS-driven
EQUITY | Sep 09, 2026, 01:03 PM UTC
L
SLXN - Silexion Therapeutics to Participate in September 2026 Industry and Investor Conferences
SLXN - Silexion Therapeutics to Participate in September 2026 Industry and Investor Conferences
EQUITY | Sep 09, 2026, 01:00 PM UTC
L
Silexion Therapeutics reports Q2 2026 financial results, business update
Silexion Therapeutics (SLXN) reports second quarter 2026 financial results and provides a business update, according to TradeXchange Newsdesk.
EARNINGS | Aug 14, 2026, 12:45 PM UTC
H
US Inflation Rate Slows To 3.4% In July
The US Consumer Price Index rose 3.4% year-over-year in July, down from June's 3.5% increase
MACRO | Aug 12, 2026, 01:42 PM UTC
M
Multiple Companies Announce Public Offerings
Several companies announce public offerings and private placements of various securities
EQUITY | Aug 12, 2026, 09:25 AM UTC
L
SLXN Launches $2.5M Public Offering
SLXN announces $2.5 million public offering at $0.65 per share
EQUITY | Aug 12, 2026, 12:24 AM UTC
L
SLXN Prices $2.5 Million Public Offering
Silexion Therapeutics announces pricing of $2.5 million public offering
EQUITY | Aug 12, 2026, 12:01 AM UTC
H
Silexion Therapeutics Reports Positive Preclinical Findings
Silexion reports positive preclinical findings for SIL204
EQUITY | Aug 04, 2026, 01:15 PM UTC
H
SLXN Initiates Phase 2/3 Trial
SLXN starts phase 2/3 trial for SIL204
EQUITY | Jul 29, 2026, 11:00 AM UTC
M
Healthcare Stocks Move
Multiple healthcare stocks are moving in Tuesday's after-market session, with some rising and others falling
EQUITY | Jun 23, 2026, 09:09 PM UTC
M
SLXN Initiates Phase 2/3 Trial
Silexion Therapeutics receives approval from Germany's BfArM to initiate Phase 2/3 clinical trial of SIL204 in locally advanced pancreatic cancer
EQUITY | Jun 23, 2026, 12:42 PM UTC